{"id":"gadobutrol-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Gadolinium retention in tissues"},{"rate":null,"effect":"Nephrogenic systemic fibrosis (NSF) risk in severe renal impairment"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gadobutrol is a macrocyclic gadolinium chelate complex used as an MRI contrast medium. It distributes into the extracellular space and enhances image contrast by paramagnetic effects on nearby water protons, improving visualization of tissues and lesions during MRI examinations. The macrocyclic structure provides high thermodynamic and kinetic stability, reducing gadolinium release.","oneSentence":"Gadobutrol is a gadolinium-based contrast agent that accumulates in tissues and enhances magnetic resonance imaging (MRI) signal by shortening T1 relaxation time.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:46.512Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"MRI contrast enhancement for diagnostic imaging of the central nervous system, body, and cardiovascular system"}]},"trialDetails":[{"nctId":"NCT03730051","phase":"PHASE4","title":"Dotarem vs Gadobutrol Contrast for Breast MRI","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2021-03-01","conditions":"Breast Diseases","enrollment":300},{"nctId":"NCT07472491","phase":"PHASE2, PHASE3","title":"A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients","status":"NOT_YET_RECRUITING","sponsor":"GE Healthcare","startDate":"2026-03-31","conditions":"Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion","enrollment":640},{"nctId":"NCT04893434","phase":"PHASE1","title":"Novel Imaging Technique to Assess Gynecologic Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-13","conditions":"Gynecologic Cancer","enrollment":20},{"nctId":"NCT07275814","phase":"PHASE3","title":"A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions","status":"RECRUITING","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2025-11-17","conditions":"For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions","enrollment":250},{"nctId":"NCT07275723","phase":"PHASE3","title":"A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions","status":"RECRUITING","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2025-11-14","conditions":"For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS)","enrollment":306},{"nctId":"NCT05229744","phase":"","title":"Prevalence of Endolymphatic Hydrops With a Hitory of Congenital Cytomegalovirus Infection","status":"TERMINATED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2022-12-15","conditions":"Endolymphatic Hydrops","enrollment":18},{"nctId":"NCT05915728","phase":"PHASE3","title":"A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-07-24","conditions":"Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology","enrollment":404},{"nctId":"NCT07040865","phase":"PHASE4","title":"Randomized Comparison of Contrast Agents Gadopiclenol and Gadobutrol in the Workup of Incidental Renal and Adrenal Findings","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-08-18","conditions":"Suspect Renal and Adrenal Imaging Findings","enrollment":104},{"nctId":"NCT03986138","phase":"PHASE3","title":"Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)","status":"COMPLETED","sponsor":"Guerbet","startDate":"2019-08-27","conditions":"Lesion in Body Region","enrollment":324},{"nctId":"NCT05762367","phase":"NA","title":"MR Lymphatic Imaging in Idiopathic Intracranial Hypertention","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2023-03-10","conditions":"Idiopathic Intracranial Hypertension","enrollment":40},{"nctId":"NCT06265272","phase":"","title":"Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-12-10","conditions":"Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension","enrollment":45},{"nctId":"NCT03996447","phase":"PHASE3","title":"Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)","status":"COMPLETED","sponsor":"Guerbet","startDate":"2019-06-03","conditions":"CNS Lesion, Blood Brain Barrier Defect","enrollment":260},{"nctId":"NCT06224543","phase":"PHASE1","title":"MR Image Synthesis With Low Gadobutrol Dose and AI","status":"COMPLETED","sponsor":"Subtle Medical","startDate":"2023-06-16","conditions":"Enhancing Brain Lesions","enrollment":60},{"nctId":"NCT05915702","phase":"PHASE3","title":"A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-07-24","conditions":"Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology","enrollment":303},{"nctId":"NCT04053842","phase":"PHASE2","title":"Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Glenn Bauman","startDate":"2021-02-04","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm","enrollment":45},{"nctId":"NCT05989022","phase":"NA","title":"Comparison of Low-dose Spiral Breast CT With MRI in Major Indications of MRI for Breast Diagnostics","status":"RECRUITING","sponsor":"AB-CT - Advanced Breast-CT GmbH","startDate":"2023-11-24","conditions":"Breast Cancer Diagnosis","enrollment":428},{"nctId":"NCT06735521","phase":"","title":"Cardiac Magnetic Resonance Stress-perfusion Study in Patinets with Fontan Circulation","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2024-04-15","conditions":"Univentricular Heart, Microvascular Dysfunction, Heart Failure","enrollment":30},{"nctId":"NCT05215132","phase":"PHASE4","title":"Investigational MRI Clinical Software and Hardware","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2019-12-19","conditions":"Image, Body","enrollment":2000},{"nctId":"NCT05515874","phase":"PHASE4","title":"Predicting Stroke Risk in ICAD With Novel MRI","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2021-08-16","conditions":"Intracranial Atherosclerosis","enrollment":100},{"nctId":"NCT03937921","phase":"","title":"Dotarem Evaluation for Myocardial Perfusion CMR","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2019-07-03","conditions":"Myocardial Perfusion Imaging, Magnetic Resonance Imaging","enrollment":90},{"nctId":"NCT02358811","phase":"","title":"Evaluation of the Impact of Sleep Apnea on Cerebral Volumetry According to Age","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2015-06-30","conditions":"Obstructive Sleep Apnea (SAOS), Aging","enrollment":69},{"nctId":"NCT00804128","phase":"","title":"Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-10-01","conditions":"Breast Cancer","enrollment":76},{"nctId":"NCT04307186","phase":"PHASE2","title":"Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-11-18","conditions":"Central Nervous System Pathology","enrollment":57},{"nctId":"NCT03602339","phase":"PHASE4","title":"Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-11-14","conditions":"Magnetic Resonance Imaging","enrollment":157},{"nctId":"NCT00027170","phase":"","title":"Technical Development of Cardiovascular Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2001-11-26","conditions":"Cardiomyopathy, Congenital Heart Disease, Cardiovascular Disease","enrollment":8781},{"nctId":"NCT03404648","phase":"PHASE3","title":"Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-11-01","conditions":"Prostate Adenocarcinoma","enrollment":19},{"nctId":"NCT01544166","phase":"PHASE1","title":"Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-05-16","conditions":"Magnetic Resonance Imaging","enrollment":44},{"nctId":"NCT04315584","phase":"EARLY_PHASE1","title":"FDG and FDOPA PET Demonstration of Functional Brain Abnormalities","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2020-03-15","conditions":"Glioblastoma","enrollment":5},{"nctId":"NCT01890434","phase":"PHASE3","title":"Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-08-26","conditions":"Coronary Artery Disease","enrollment":478},{"nctId":"NCT02796729","phase":"PHASE2","title":"CEST- Glucose Enhanced MRI for Metastatic Brain Tumours","status":"TERMINATED","sponsor":"British Columbia Cancer Agency","startDate":"2016-10","conditions":"Brain Neoplasms, Malignant, Metastasis","enrollment":3},{"nctId":"NCT01344447","phase":"PHASE3","title":"Gadobutrol Enhanced MRA of the Supra-aortic Vessels","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-05-12","conditions":"Carotid Stenosis","enrollment":479},{"nctId":"NCT02902588","phase":"NA","title":"Blood-brain Barrier Permeability Study in Adults With Meningitis","status":"TERMINATED","sponsor":"Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences","startDate":"2015-08-01","conditions":"Blood-Brain Barrier Permeability","enrollment":20},{"nctId":"NCT01989000","phase":"NA","title":"The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-11","conditions":"Pancreatic Cancer","enrollment":47},{"nctId":"NCT01890421","phase":"PHASE3","title":"Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-07-19","conditions":"Coronary Artery Disease","enrollment":426},{"nctId":"NCT02350426","phase":"PHASE1","title":"A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2015-08-12","conditions":"Arthritis, Rheumatoid","enrollment":10},{"nctId":"NCT00522951","phase":"PHASE3","title":"SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-08","conditions":"Brain Metastases","enrollment":165},{"nctId":"NCT02217280","phase":"NA","title":"Dispersal Pattern for Spine Injections (Gadolinium Contrast)","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2015-04","conditions":"Cervical Radiculopathy","enrollment":20},{"nctId":"NCT02550951","phase":"NA","title":"Utility of MR Lymphangiography in Postoperative Follow-up of Lymphedema: Comparison With Lymphoscintigraphy","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2014-10","conditions":"Lymphedema","enrollment":7},{"nctId":"NCT01344460","phase":"PHASE3","title":"Gadobutrol Enhanced MRA of the Renal Arteries","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-05","conditions":"Renal Artery Obstruction","enrollment":317},{"nctId":"NCT00468819","phase":"PHASE1","title":"A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-05","conditions":"Magnetic Resonance Imaging","enrollment":140},{"nctId":"NCT00395460","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-09","conditions":"Central Nervous System Diseases","enrollment":147},{"nctId":"NCT01050829","phase":"PHASE3","title":"Gadobutrol Magnevist-controlled Body Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-01","conditions":"Magnetic Resonance Imaging","enrollment":370},{"nctId":"NCT01104584","phase":"PHASE3","title":"Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-05","conditions":"Breast Cancer","enrollment":460},{"nctId":"NCT01067976","phase":"PHASE3","title":"Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-02","conditions":"Breast Cancer, Diagnostic Imaging","enrollment":446},{"nctId":"NCT01660841","phase":"PHASE3","title":"Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-09","conditions":"Magnetic Resonance Imaging","enrollment":223},{"nctId":"NCT01490294","phase":"PHASE2","title":"Myocardial Perfusion MRI","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":"Myocardial Perfusion Imaging, Magnetic Resonance Imaging","enrollment":232},{"nctId":"NCT00623467","phase":"PHASE3","title":"Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-12","conditions":"Central Nervous System Diseases","enrollment":343},{"nctId":"NCT00862459","phase":"PHASE2","title":"Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-08","conditions":"Brain Diseases, Spinal Cord Diseases","enrollment":237},{"nctId":"NCT00395733","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-10","conditions":"Vascular Diseases","enrollment":83},{"nctId":"NCT00861172","phase":"NA","title":"Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2009-02","conditions":"Lesions, Multiple Sclerosis","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gadobutrol Injection","genericName":"Gadobutrol Injection","companyName":"Shanghai Shengdi Pharmaceutical Co., Ltd","companyId":"shanghai-shengdi-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gadobutrol is a gadolinium-based contrast agent that accumulates in tissues and enhances magnetic resonance imaging (MRI) signal by shortening T1 relaxation time. Used for MRI contrast enhancement for diagnostic imaging of the central nervous system, body, and cardiovascular system.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}